JP2025513588A5 - - Google Patents
Info
- Publication number
- JP2025513588A5 JP2025513588A5 JP2024563035A JP2024563035A JP2025513588A5 JP 2025513588 A5 JP2025513588 A5 JP 2025513588A5 JP 2024563035 A JP2024563035 A JP 2024563035A JP 2024563035 A JP2024563035 A JP 2024563035A JP 2025513588 A5 JP2025513588 A5 JP 2025513588A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263334365P | 2022-04-25 | 2022-04-25 | |
| US63/334,365 | 2022-04-25 | ||
| PCT/IL2023/050426 WO2023209716A1 (en) | 2022-04-25 | 2023-04-25 | Anti-ilt3 antibodies and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513588A JP2025513588A (ja) | 2025-04-24 |
| JP2025513588A5 true JP2025513588A5 (https=) | 2026-05-07 |
Family
ID=86604937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563035A Pending JP2025513588A (ja) | 2022-04-25 | 2023-04-25 | 抗ｉｌｔ３抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250277032A1 (https=) |
| EP (1) | EP4514472A1 (https=) |
| JP (1) | JP2025513588A (https=) |
| KR (1) | KR20250025354A (https=) |
| CN (1) | CN119487072A (https=) |
| AU (1) | AU2023258644A1 (https=) |
| CA (1) | CA3249138A1 (https=) |
| IL (1) | IL316523A (https=) |
| WO (1) | WO2023209716A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025062392A1 (en) * | 2023-09-20 | 2025-03-27 | Biond Biologics Ltd. | Anti-ilt3 blockade combinations |
| WO2025141589A1 (en) | 2023-12-31 | 2025-07-03 | Biond Biologics Ltd. | Treatment of cancer with anti-ilt3 antibodies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| WO2013033734A1 (en) * | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
| CA2977544C (en) * | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| EP3538141A4 (en) | 2016-11-10 | 2020-07-15 | Merck Sharp & Dohme Corp. | LIGAND ILT3 |
| WO2018148494A1 (en) * | 2017-02-09 | 2018-08-16 | Bluefin Biomedicine, Inc. | Anti-ilt3 antibodies and antibody drug conjugates |
| CN111712518B (zh) | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
| CA3109366A1 (en) | 2018-09-13 | 2020-03-19 | The Board Of Regents Of The University Of Texas System | Novel lilrb4 antibodies and uses thereof |
| JP2022522775A (ja) * | 2019-03-01 | 2022-04-20 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｌｉｌｒｂ４結合抗体およびその使用方法 |
| PH12022551462A1 (en) | 2019-12-19 | 2023-11-13 | Ngm Biopharmaceuticals Inc | Ilt3-binding agents and methods of use thereof |
| AU2021236302A1 (en) * | 2020-03-12 | 2022-10-20 | Immune-Onc Therapeutics, Inc. | Novel anti-LILRB4 antibodies and derivative products |
-
2023
- 2023-04-25 AU AU2023258644A patent/AU2023258644A1/en active Pending
- 2023-04-25 EP EP23727099.6A patent/EP4514472A1/en active Pending
- 2023-04-25 CA CA3249138A patent/CA3249138A1/en active Pending
- 2023-04-25 JP JP2024563035A patent/JP2025513588A/ja active Pending
- 2023-04-25 IL IL316523A patent/IL316523A/en unknown
- 2023-04-25 CN CN202380048621.4A patent/CN119487072A/zh active Pending
- 2023-04-25 WO PCT/IL2023/050426 patent/WO2023209716A1/en not_active Ceased
- 2023-04-25 KR KR1020247037976A patent/KR20250025354A/ko active Pending
- 2023-04-25 US US18/858,887 patent/US20250277032A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7482287B2 (ja) | がん処置のためのカドヘリン－１７特異的抗体及び細胞傷害性細胞 | |
| CN104169303B (zh) | 癌的治疗和/或预防用药物组合物 | |
| US8901278B2 (en) | Pharmaceutical antibody compositions with resistance to soluble CEA | |
| JP2022515318A5 (https=) | ||
| JP2022058345A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| WO2023206350A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| JP2024527606A5 (https=) | ||
| HUE030130T2 (en) | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer | |
| JP2025513588A5 (https=) | ||
| WO2018117237A1 (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP2022514734A5 (https=) | ||
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| JP2023537396A (ja) | Ｉｌｔ２に対する抗体およびその使用 | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2023549555A5 (https=) | ||
| JP2022506761A5 (https=) | ||
| JP2023530720A (ja) | Ｌｅｗｉｓ Ｙに対するヒト化抗体 | |
| JP2024527043A5 (https=) | ||
| CN114728058A (zh) | Fgfr4/pd-1组合治疗 | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| JP2025535502A (ja) | 抗ｗｔ１／ｈｌａ抗体及びその使用 | |
| JP2024529907A5 (https=) | ||
| WO2024051752A1 (en) | Multispecific constructs and uses thereof |